摘要
2019年诺贝尔生理学或医学奖表彰了"细胞氧感知和适应"机制的创新发现,其相关机制与慢性肾性贫血的病理生理过程息息相关。近年来,基于氧感知通路的肾性贫血药物研发硕果累累。目前研究的重点是低氧诱导因子脯氨酰羟化酶抑制剂,主要有6种药物,均为口服制剂,可稳定升高促红细胞生成素及血红蛋白,同时可改善铁代谢,部分已经上市,部分还处于临床研究阶段。罗沙司他作为由2019年诺贝尔生理学或医学奖研究成果衍生的唯一上市的新药,是转化医学的典范,且在我国首发上市,我国在历史上首次成为全球首先批准首创作用机制药物的国家。就这一研究发现以及依据这一新机制研发的抗肾性贫血新药的研究现状进行总结。
Nobel Prize in Physiology or Medicine 2019 has been awarded for the elucidation of oxygen sensing systems and adaptation,which is linked to the pathophysiological processes of chronic renal anemia.In recent years,there have been great achievements of research on drugs for renal anemia based on oxygen sensing pathway.Current focus of research is on the hypoxiainducible factor(HIF)-prolyl hydroxylase inhibitor(PHI),mainly with six drugs(all oral preparations),which can steadily increase the level of erythropoietin(EPO)and hemoglobin(Hb)and improve iron metabolism.Some of them have already been on the market,while others are still under clinical research.As the only new drug on the market derived from the 2019 Nobel Prize in Physiology or Medicine,roxadustat is a model of translational medicine.Its debut in China makes China the first country in the world that approves the drug with initiative mechanism.This paper summarizes the findings of HIF-PHI and the research status of anti-renal anemia drugs based on this new mechanism.
作者
张晓良
仰欣
涂岩
ZHANG Xiaoliang;YANG Xin;TU Yan(Department of Nephrology,Southeast University Zhongda Hospital,Nanjing 210009,China)
出处
《药学进展》
CAS
2019年第12期914-921,共8页
Progress in Pharmaceutical Sciences
基金
国家自然科学基金(No.81570612,No.81870497)
